Bristol Myers Squibb Company $BMY Holdings Lifted by Ethic Inc.

Ethic Inc. grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 10.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 298,064 shares of the biopharmaceutical company’s stock after acquiring an additional 27,160 shares during the quarter. Ethic Inc.’s holdings in Bristol Myers Squibb were worth $18,599,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Primecap Management Co. CA purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $1,436,115,000. Legal & General Group Plc bought a new position in Bristol Myers Squibb in the 2nd quarter worth about $980,862,000. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp grew its position in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec purchased a new stake in Bristol Myers Squibb during the 2nd quarter valued at about $243,646,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares of the company’s stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on BMY shares. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Cantor Fitzgerald dropped their target price on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. Daiwa Securities Group increased their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $76.00 price target on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $65.46.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $62.20 on Friday. The stock has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The business’s fifty day moving average price is $62.34 and its 200-day moving average price is $60.11.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 earnings per share. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.